



Trapped Awake: The Devastating Reality of Fatal Familial Insomnia

Husna Irfan Thalib*

General Medicine Practice Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia

Corresponding Author: General Medicine Practice Program, Batterjee Medical College, Jeddah 21442, Saudi Arabia.

Received: September 22, 2024; **Published:** September 30, 2024

Sleep is often regarded as one of the most essential processes for human survival. We spend nearly a third of our lives sleeping, and though much about sleep remains a mystery, its vital functions for both the mind and body are undeniable. But what if the very act of sleep — a necessity for life — became physically impossible? This is a devastating reality for individuals suffering from Fatal Familial Insomnia (FFI), a rare and incurable genetic disorder that causes a total inability to sleep, ultimately leading to death.

Fatal Familial Insomnia is a part of a group of conditions known as prion diseases, caused by abnormally folded proteins, or prions, that accumulate in the brain and cause widespread damage. FFI is especially unique because these prions specifically target the thalamus, the brain region responsible for regulating the sleep-wake cycle and various sensory and motor signals [1]. This precise targeting of sleep regulation centers distinguishes FFI from other neurodegenerative diseases like Alzheimer's or Creutzfeldt-Jakob disease, which have broader impacts on cognition and motor function. This disease is inherited in an autosomal dominant fashion, meaning that if one parent carries the mutation in the PRNP gene (which codes for the prion protein), there is a 50% chance of passing it on to their offspring. Despite this, FFI is extraordinarily rare, with only about 40 families worldwide known to carry the mutation [2].

What is even more insidious is that FFI typically remains dormant for decades. Many individuals live perfectly normal lives until symptoms begin to appear, usually between the ages of 30 and 60. Once the disease manifests, however, it progresses rapidly, with initial symptoms often resembling common insomnia [3]. Over time, however, it becomes clear that this is no ordinary sleeplessness. No matter what medications or sedatives are used, the person is unable to achieve restorative sleep. This prolonged wakefulness wreaks havoc on the body and mind.

FFI progresses through four distinct stages. In the first stage, which can last for several months, the person experiences increasing insomnia, anxiety, and panic attacks. Sleep disturbances start subtly, but soon, even short naps or brief moments of rest become impossible. The body responds to this prolonged lack of sleep with profound autonomic dysfunction, including rapid heart rate, excessive sweating, and elevated blood pressure. This disruption of the autonomic nervous system exacerbates the patient's physical deterioration. In the second stage,

which also lasts a few months, hallucinations begin to appear. These are not simply vivid dreams but are waking delusions, where patients may see or hear things that aren't there. At this point, they are completely unable to sleep and may experience extreme confusion and paranoia. The third stage is marked by a rapid decline in cognitive function, which resembles advanced dementia. The person may lose the ability to speak coherently, recognize family members, or perform even basic tasks. Weight loss, muscle atrophy, and a weakened immune system often accompany this decline, as the body starts to fail without the regenerative properties of sleep. In the final stage, the patient slips into a coma, from which they will not awaken [4]. Death typically follows within 12 to 18 months from the onset of symptoms. There is no cure, and treatment options remain extremely limited — primarily palliative care to manage symptoms and ease discomfort [5].

Despite significant advances in understanding prion diseases, the precise mechanism by which FFI disrupts sleep remains poorly understood. The prion protein, when misfolded, aggregates and causes irreversible damage to neurons. In FFI, the thalamus — a critical hub for regulating sleep, consciousness, and sensory input — is the primary target. Damage to the thalamus prevents the normal transitions between sleep and wakefulness, effectively trapping the brain in a perpetual state of alertness. This relentless wakefulness is unlike traditional insomnia, where individuals may be able to fall asleep for short periods. In FFI, the brain is fundamentally unable to initiate sleep. Studies using functional imaging techniques have shown that the thalamus becomes progressively atrophied, losing its ability to relay signals that would typically induce sleep [6].

It's not just the lack of sleep that causes problems, though. The thalamus also plays a crucial role in the body's autonomic functions, such as heart rate and body temperature regulation. As the disease progresses, patients experience unpredictable surges in blood pressure, irregular heartbeats, and other signs of autonomic failure. These effects, combined with severe cognitive decline, contribute to the rapid progression and poor prognosis of the disease.

Given how rare FFI is, research into potential treatments has been limited. However, the study of prion diseases like FFI has far-reaching implications for other neurodegenerative conditions,

including Alzheimer's and Parkinson's disease, which also involve the accumulation of misfolded proteins. While prion diseases are currently untreatable, they provide a model for understanding how protein misfolding can lead to brain degeneration. There has also been some progress in experimental treatments, such as gene-silencing therapies, which aim to prevent the production of the misfolded prion protein in the first place. However, these treatments are still in very early stages of research and not yet available for clinical use [7]. One experimental approach has been to focus on targeting prion replication. In theory, if we can stop prions from replicating and spreading through the brain, we may be able to slow or halt the progression of FFI and similar diseases. However, the challenge lies in the fact that prions are extremely resistant to traditional treatments like radiation, heat, and even protease enzymes, which normally break down proteins [5-7].

Fatal Familial Insomnia is a reminder of how crucial sleep is to maintaining life. While many of us may think of sleep as a passive state, it is one of the most active processes our bodies undergo. Sleep is when the brain performs essential maintenance: it clears out toxic waste products, repairs neurons, and consolidates memories. For now, FFI remains a tragic and incurable condition. Understanding the disease could one day pave the way to breakthroughs in treating not just prion diseases but other neurodegenerative conditions that affect millions of people worldwide.

References

1. Khan Z, Sankari A, Bollu PC et al, (2024) "Fatal Familial Insomnia", *StatPearls Publishing*.
2. Cracco L, Appleby BS, Gambetti P. et al; (2018) "Fatal familial insomnia and sporadic fatal insomnia" *Handb Clin Neurol*; 153: pp271-299. doi: 10.1016/B978-0-444-63945-5.00015-5.
3. Kortazar-Zubizarreta I, Eraña H, et al; (2023) "Analysis of a large case series of fatal familial insomnia to determine tests with the highest diagnostic value", *J Neuropathol Exp Neurol*; 82(2): pp69-179. doi: 10.1093/jnen/nlac113.
4. Llorens F, Zarranz JJ, et al; (2017) "Fatal Familial Insomnia: Clinical Aspects and Molecular Alterations", *Curr Neurol Neurosci Rep*; 17(4): pp30. doi: 10.1007/s11910-017-0743-0.
5. Chu M, Xie K, Zhang J, et al; (2022) "Proposal of new diagnostic criteria for fatal familial insomnia", *J Neurol*; 269(9): pp4909-4919. doi: 10.1007/s00415-022-11135-6. Epub 2022 May 3.
6. Yang TW, Park B, et al; (2018) "Fatal familial insomnia presenting with agrypnia excitata and very low atonia index level: A case report and literature review" *Medicine (Baltimore)*; 97(18): pp0646. doi: 10.1097/MD.0000000000010646.
7. Zhang J, Chu M, et al., (2022) "Clinical profile of fatal familial insomnia: phenotypic variation in 129 polymorphisms and geographical regions", *J Neurol Neurosurg Psychiatry*; 93(3): pp291-297. doi: 10.1136/jnnp-2021-327247.